ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurometabolic Disorders Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-26V5841
Home | Market Reports | Health| Pharmacy
Global Neurometabolic Disorders Market Insights Forecast to 2028
BUY CHAPTERS

Global Neurometabolic Disorders Market Research Report 2025

Code: QYRE-Auto-26V5841
Report
July 2025
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Amicus Therapeutics
ISU ABXIS
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix Biotherapeutics
BioMarin
Genzyme
Shire Plc
Greencross
Amicus

Neurometabolic Disorders Market Size

The global market for Neurometabolic Disorders was valued at US$ 1363 million in the year 2024 and is projected to reach a revised size of US$ 1847 million by 2031, growing at a CAGR of 4.5% during the forecast period.

Neurometabolic Disorders Market

Neurometabolic Disorders Market

Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
The Neurometabolic Disorders Market is driven by the increasing awareness and understanding of rare inherited metabolic disorders that affect the nervous system. These disorders, such as phenylketonuria and lysosomal storage diseases, require specialized treatments and therapies to manage symptoms and improve the quality of life for affected individuals. As advancements in genetics and diagnostics progress, the demand for research, development, and access to therapies and interventions for neurometabolic disorders continues to grow. These therapies often involve enzyme replacement therapy, gene therapy, or small molecule drugs, aiming to address the underlying metabolic abnormalities associated with these conditions. However, a key challenge for this market is the need to overcome the high cost of treatment and ensure that individuals with these rare disorders have equitable access to life-changing therapies. Regulatory approval, early diagnosis, and addressing potential side effects of treatments are ongoing challenges. Additionally, the market faces competition from other rare diseases, necessitating continuous research and efforts to mobilize resources and global commitment to improving the lives of those affected by neurometabolic disorders. Balancing innovation, affordability, and accessibility while addressing the unique challenges of these conditions is vital for the continued growth of the Neurometabolic Disorders Market.
This report aims to provide a comprehensive presentation of the global market for Neurometabolic Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurometabolic Disorders.
The Neurometabolic Disorders market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurometabolic Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurometabolic Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Neurometabolic Disorders Market Report

Report Metric Details
Report Name Neurometabolic Disorders Market
Accounted market size in year US$ 1363 million
Forecasted market size in 2031 US$ 1847 million
CAGR 4.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Oral
  • Parenteral
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation, Lixte Biotechnology, Neuraltus Pharmaceuticals, Protalix, Pharming Group, Protalix BioTherapeutics, Amicus, Biomarin, Genzyme, Shire, Greencross
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Neurometabolic Disorders company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Neurometabolic Disorders Market growing?

Ans: The Neurometabolic Disorders Market witnessing a CAGR of 4.5% during the forecast period 2025-2031.

What is the Neurometabolic Disorders Market size in 2031?

Ans: The Neurometabolic Disorders Market size in 2031 will be US$ 1847 million.

Who are the main players in the Neurometabolic Disorders Market report?

Ans: The main players in the Neurometabolic Disorders Market are Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation, Lixte Biotechnology, Neuraltus Pharmaceuticals, Protalix, Pharming Group, Protalix BioTherapeutics, Amicus, Biomarin, Genzyme, Shire, Greencross

What are the Application segmentation covered in the Neurometabolic Disorders Market report?

Ans: The Applications covered in the Neurometabolic Disorders Market report are Oral, Parenteral

What are the Type segmentation covered in the Neurometabolic Disorders Market report?

Ans: The Types covered in the Neurometabolic Disorders Market report are Gaucher’s Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis VI, Other

Recommended Reports

Rare Genetic Disorders

Lysosomal Storage Diseases

Neurometabolic & CNS Diseases

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurometabolic Disorders Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Gaucher’s Disease
1.2.3 Fabry Disease
1.2.4 Pompe Disease
1.2.5 Mucopolysaccharidosis VI
1.2.6 Other
1.3 Market by Application
1.3.1 Global Neurometabolic Disorders Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Oral
1.3.3 Parenteral
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurometabolic Disorders Market Perspective (2020-2031)
2.2 Global Neurometabolic Disorders Growth Trends by Region
2.2.1 Global Neurometabolic Disorders Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neurometabolic Disorders Historic Market Size by Region (2020-2025)
2.2.3 Neurometabolic Disorders Forecasted Market Size by Region (2026-2031)
2.3 Neurometabolic Disorders Market Dynamics
2.3.1 Neurometabolic Disorders Industry Trends
2.3.2 Neurometabolic Disorders Market Drivers
2.3.3 Neurometabolic Disorders Market Challenges
2.3.4 Neurometabolic Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurometabolic Disorders Players by Revenue
3.1.1 Global Top Neurometabolic Disorders Players by Revenue (2020-2025)
3.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2020-2025)
3.2 Global Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neurometabolic Disorders Revenue
3.4 Global Neurometabolic Disorders Market Concentration Ratio
3.4.1 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurometabolic Disorders Revenue in 2024
3.5 Global Key Players of Neurometabolic Disorders Head office and Area Served
3.6 Global Key Players of Neurometabolic Disorders, Product and Application
3.7 Global Key Players of Neurometabolic Disorders, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurometabolic Disorders Breakdown Data by Type
4.1 Global Neurometabolic Disorders Historic Market Size by Type (2020-2025)
4.2 Global Neurometabolic Disorders Forecasted Market Size by Type (2026-2031)
5 Neurometabolic Disorders Breakdown Data by Application
5.1 Global Neurometabolic Disorders Historic Market Size by Application (2020-2025)
5.2 Global Neurometabolic Disorders Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neurometabolic Disorders Market Size (2020-2031)
6.2 North America Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neurometabolic Disorders Market Size by Country (2020-2025)
6.4 North America Neurometabolic Disorders Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurometabolic Disorders Market Size (2020-2031)
7.2 Europe Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neurometabolic Disorders Market Size by Country (2020-2025)
7.4 Europe Neurometabolic Disorders Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurometabolic Disorders Market Size (2020-2031)
8.2 Asia-Pacific Neurometabolic Disorders Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neurometabolic Disorders Market Size by Region (2020-2025)
8.4 Asia-Pacific Neurometabolic Disorders Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurometabolic Disorders Market Size (2020-2031)
9.2 Latin America Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neurometabolic Disorders Market Size by Country (2020-2025)
9.4 Latin America Neurometabolic Disorders Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurometabolic Disorders Market Size (2020-2031)
10.2 Middle East & Africa Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neurometabolic Disorders Market Size by Country (2020-2025)
10.4 Middle East & Africa Neurometabolic Disorders Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amicus Therapeutics
11.1.1 Amicus Therapeutics Company Details
11.1.2 Amicus Therapeutics Business Overview
11.1.3 Amicus Therapeutics Neurometabolic Disorders Introduction
11.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2020-2025)
11.1.5 Amicus Therapeutics Recent Development
11.2 ISU Abxis
11.2.1 ISU Abxis Company Details
11.2.2 ISU Abxis Business Overview
11.2.3 ISU Abxis Neurometabolic Disorders Introduction
11.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2020-2025)
11.2.5 ISU Abxis Recent Development
11.3 JCR Pharmaceuticals
11.3.1 JCR Pharmaceuticals Company Details
11.3.2 JCR Pharmaceuticals Business Overview
11.3.3 JCR Pharmaceuticals Neurometabolic Disorders Introduction
11.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2020-2025)
11.3.5 JCR Pharmaceuticals Recent Development
11.4 Biosidus
11.4.1 Biosidus Company Details
11.4.2 Biosidus Business Overview
11.4.3 Biosidus Neurometabolic Disorders Introduction
11.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2020-2025)
11.4.5 Biosidus Recent Development
11.5 Greenovation Biotech
11.5.1 Greenovation Biotech Company Details
11.5.2 Greenovation Biotech Business Overview
11.5.3 Greenovation Biotech Neurometabolic Disorders Introduction
11.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2020-2025)
11.5.5 Greenovation Biotech Recent Development
11.6 UAB Proforma
11.6.1 UAB Proforma Company Details
11.6.2 UAB Proforma Business Overview
11.6.3 UAB Proforma Neurometabolic Disorders Introduction
11.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2020-2025)
11.6.5 UAB Proforma Recent Development
11.7 Dong-A Socio Group
11.7.1 Dong-A Socio Group Company Details
11.7.2 Dong-A Socio Group Business Overview
11.7.3 Dong-A Socio Group Neurometabolic Disorders Introduction
11.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2020-2025)
11.7.5 Dong-A Socio Group Recent Development
11.8 ExSAR Corporation
11.8.1 ExSAR Corporation Company Details
11.8.2 ExSAR Corporation Business Overview
11.8.3 ExSAR Corporation Neurometabolic Disorders Introduction
11.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2020-2025)
11.8.5 ExSAR Corporation Recent Development
11.9 Lixte Biotechnology
11.9.1 Lixte Biotechnology Company Details
11.9.2 Lixte Biotechnology Business Overview
11.9.3 Lixte Biotechnology Neurometabolic Disorders Introduction
11.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2020-2025)
11.9.5 Lixte Biotechnology Recent Development
11.10 Neuraltus Pharmaceuticals
11.10.1 Neuraltus Pharmaceuticals Company Details
11.10.2 Neuraltus Pharmaceuticals Business Overview
11.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Introduction
11.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2020-2025)
11.10.5 Neuraltus Pharmaceuticals Recent Development
11.11 Protalix
11.11.1 Protalix Company Details
11.11.2 Protalix Business Overview
11.11.3 Protalix Neurometabolic Disorders Introduction
11.11.4 Protalix Revenue in Neurometabolic Disorders Business (2020-2025)
11.11.5 Protalix Recent Development
11.12 Pharming Group
11.12.1 Pharming Group Company Details
11.12.2 Pharming Group Business Overview
11.12.3 Pharming Group Neurometabolic Disorders Introduction
11.12.4 Pharming Group Revenue in Neurometabolic Disorders Business (2020-2025)
11.12.5 Pharming Group Recent Development
11.13 Protalix BioTherapeutics
11.13.1 Protalix BioTherapeutics Company Details
11.13.2 Protalix BioTherapeutics Business Overview
11.13.3 Protalix BioTherapeutics Neurometabolic Disorders Introduction
11.13.4 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2020-2025)
11.13.5 Protalix BioTherapeutics Recent Development
11.14 Amicus
11.14.1 Amicus Company Details
11.14.2 Amicus Business Overview
11.14.3 Amicus Neurometabolic Disorders Introduction
11.14.4 Amicus Revenue in Neurometabolic Disorders Business (2020-2025)
11.14.5 Amicus Recent Development
11.15 Biomarin
11.15.1 Biomarin Company Details
11.15.2 Biomarin Business Overview
11.15.3 Biomarin Neurometabolic Disorders Introduction
11.15.4 Biomarin Revenue in Neurometabolic Disorders Business (2020-2025)
11.15.5 Biomarin Recent Development
11.16 Genzyme
11.16.1 Genzyme Company Details
11.16.2 Genzyme Business Overview
11.16.3 Genzyme Neurometabolic Disorders Introduction
11.16.4 Genzyme Revenue in Neurometabolic Disorders Business (2020-2025)
11.16.5 Genzyme Recent Development
11.17 Shire
11.17.1 Shire Company Details
11.17.2 Shire Business Overview
11.17.3 Shire Neurometabolic Disorders Introduction
11.17.4 Shire Revenue in Neurometabolic Disorders Business (2020-2025)
11.17.5 Shire Recent Development
11.18 Greencross
11.18.1 Greencross Company Details
11.18.2 Greencross Business Overview
11.18.3 Greencross Neurometabolic Disorders Introduction
11.18.4 Greencross Revenue in Neurometabolic Disorders Business (2020-2025)
11.18.5 Greencross Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Amicus Therapeutics
ISU ABXIS
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix Biotherapeutics
BioMarin
Genzyme
Shire Plc
Greencross
Amicus
List of Tables
 Table 1. Global Neurometabolic Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Gaucher’s Disease
 Table 3. Key Players of Fabry Disease
 Table 4. Key Players of Pompe Disease
 Table 5. Key Players of Mucopolysaccharidosis VI
 Table 6. Key Players of Other
 Table 7. Global Neurometabolic Disorders Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Neurometabolic Disorders Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Neurometabolic Disorders Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Neurometabolic Disorders Market Share by Region (2020-2025)
 Table 11. Global Neurometabolic Disorders Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Neurometabolic Disorders Market Share by Region (2026-2031)
 Table 13. Neurometabolic Disorders Market Trends
 Table 14. Neurometabolic Disorders Market Drivers
 Table 15. Neurometabolic Disorders Market Challenges
 Table 16. Neurometabolic Disorders Market Restraints
 Table 17. Global Neurometabolic Disorders Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Neurometabolic Disorders Market Share by Players (2020-2025)
 Table 19. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurometabolic Disorders as of 2024)
 Table 20. Ranking of Global Top Neurometabolic Disorders Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Neurometabolic Disorders Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Neurometabolic Disorders, Headquarters and Area Served
 Table 23. Global Key Players of Neurometabolic Disorders, Product and Application
 Table 24. Global Key Players of Neurometabolic Disorders, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Neurometabolic Disorders Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Neurometabolic Disorders Revenue Market Share by Type (2020-2025)
 Table 28. Global Neurometabolic Disorders Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Neurometabolic Disorders Revenue Market Share by Type (2026-2031)
 Table 30. Global Neurometabolic Disorders Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Neurometabolic Disorders Revenue Market Share by Application (2020-2025)
 Table 32. Global Neurometabolic Disorders Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Neurometabolic Disorders Revenue Market Share by Application (2026-2031)
 Table 34. North America Neurometabolic Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Neurometabolic Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Neurometabolic Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Neurometabolic Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Neurometabolic Disorders Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Neurometabolic Disorders Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Neurometabolic Disorders Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Neurometabolic Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Neurometabolic Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Neurometabolic Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Neurometabolic Disorders Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Amicus Therapeutics Company Details
 Table 50. Amicus Therapeutics Business Overview
 Table 51. Amicus Therapeutics Neurometabolic Disorders Product
 Table 52. Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 53. Amicus Therapeutics Recent Development
 Table 54. ISU Abxis Company Details
 Table 55. ISU Abxis Business Overview
 Table 56. ISU Abxis Neurometabolic Disorders Product
 Table 57. ISU Abxis Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 58. ISU Abxis Recent Development
 Table 59. JCR Pharmaceuticals Company Details
 Table 60. JCR Pharmaceuticals Business Overview
 Table 61. JCR Pharmaceuticals Neurometabolic Disorders Product
 Table 62. JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 63. JCR Pharmaceuticals Recent Development
 Table 64. Biosidus Company Details
 Table 65. Biosidus Business Overview
 Table 66. Biosidus Neurometabolic Disorders Product
 Table 67. Biosidus Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 68. Biosidus Recent Development
 Table 69. Greenovation Biotech Company Details
 Table 70. Greenovation Biotech Business Overview
 Table 71. Greenovation Biotech Neurometabolic Disorders Product
 Table 72. Greenovation Biotech Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 73. Greenovation Biotech Recent Development
 Table 74. UAB Proforma Company Details
 Table 75. UAB Proforma Business Overview
 Table 76. UAB Proforma Neurometabolic Disorders Product
 Table 77. UAB Proforma Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 78. UAB Proforma Recent Development
 Table 79. Dong-A Socio Group Company Details
 Table 80. Dong-A Socio Group Business Overview
 Table 81. Dong-A Socio Group Neurometabolic Disorders Product
 Table 82. Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 83. Dong-A Socio Group Recent Development
 Table 84. ExSAR Corporation Company Details
 Table 85. ExSAR Corporation Business Overview
 Table 86. ExSAR Corporation Neurometabolic Disorders Product
 Table 87. ExSAR Corporation Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 88. ExSAR Corporation Recent Development
 Table 89. Lixte Biotechnology Company Details
 Table 90. Lixte Biotechnology Business Overview
 Table 91. Lixte Biotechnology Neurometabolic Disorders Product
 Table 92. Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 93. Lixte Biotechnology Recent Development
 Table 94. Neuraltus Pharmaceuticals Company Details
 Table 95. Neuraltus Pharmaceuticals Business Overview
 Table 96. Neuraltus Pharmaceuticals Neurometabolic Disorders Product
 Table 97. Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 98. Neuraltus Pharmaceuticals Recent Development
 Table 99. Protalix Company Details
 Table 100. Protalix Business Overview
 Table 101. Protalix Neurometabolic Disorders Product
 Table 102. Protalix Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 103. Protalix Recent Development
 Table 104. Pharming Group Company Details
 Table 105. Pharming Group Business Overview
 Table 106. Pharming Group Neurometabolic Disorders Product
 Table 107. Pharming Group Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 108. Pharming Group Recent Development
 Table 109. Protalix BioTherapeutics Company Details
 Table 110. Protalix BioTherapeutics Business Overview
 Table 111. Protalix BioTherapeutics Neurometabolic Disorders Product
 Table 112. Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 113. Protalix BioTherapeutics Recent Development
 Table 114. Amicus Company Details
 Table 115. Amicus Business Overview
 Table 116. Amicus Neurometabolic Disorders Product
 Table 117. Amicus Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 118. Amicus Recent Development
 Table 119. Biomarin Company Details
 Table 120. Biomarin Business Overview
 Table 121. Biomarin Neurometabolic Disorders Product
 Table 122. Biomarin Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 123. Biomarin Recent Development
 Table 124. Genzyme Company Details
 Table 125. Genzyme Business Overview
 Table 126. Genzyme Neurometabolic Disorders Product
 Table 127. Genzyme Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 128. Genzyme Recent Development
 Table 129. Shire Company Details
 Table 130. Shire Business Overview
 Table 131. Shire Neurometabolic Disorders Product
 Table 132. Shire Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 133. Shire Recent Development
 Table 134. Greencross Company Details
 Table 135. Greencross Business Overview
 Table 136. Greencross Neurometabolic Disorders Product
 Table 137. Greencross Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million)
 Table 138. Greencross Recent Development
 Table 139. Research Programs/Design for This Report
 Table 140. Key Data Information from Secondary Sources
 Table 141. Key Data Information from Primary Sources
 Table 142. Authors List of This Report


List of Figures
 Figure 1. Neurometabolic Disorders Picture
 Figure 2. Global Neurometabolic Disorders Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neurometabolic Disorders Market Share by Type: 2024 VS 2031
 Figure 4. Gaucher’s Disease Features
 Figure 5. Fabry Disease Features
 Figure 6. Pompe Disease Features
 Figure 7. Mucopolysaccharidosis VI Features
 Figure 8. Other Features
 Figure 9. Global Neurometabolic Disorders Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Neurometabolic Disorders Market Share by Application: 2024 VS 2031
 Figure 11. Oral Case Studies
 Figure 12. Parenteral Case Studies
 Figure 13. Neurometabolic Disorders Report Years Considered
 Figure 14. Global Neurometabolic Disorders Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Neurometabolic Disorders Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Neurometabolic Disorders Market Share by Region: 2024 VS 2031
 Figure 17. Global Neurometabolic Disorders Market Share by Players in 2024
 Figure 18. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurometabolic Disorders as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Neurometabolic Disorders Revenue in 2024
 Figure 20. North America Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Neurometabolic Disorders Market Share by Country (2020-2031)
 Figure 22. United States Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Neurometabolic Disorders Market Share by Country (2020-2031)
 Figure 26. Germany Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Neurometabolic Disorders Market Share by Region (2020-2031)
 Figure 34. China Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Neurometabolic Disorders Market Share by Country (2020-2031)
 Figure 42. Mexico Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Neurometabolic Disorders Market Share by Country (2020-2031)
 Figure 46. Turkey Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Amicus Therapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 50. ISU Abxis Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 51. JCR Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 52. Biosidus Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 53. Greenovation Biotech Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 54. UAB Proforma Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 55. Dong-A Socio Group Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 56. ExSAR Corporation Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 57. Lixte Biotechnology Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 58. Neuraltus Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 59. Protalix Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 60. Pharming Group Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 61. Protalix BioTherapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 62. Amicus Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 63. Biomarin Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 64. Genzyme Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 65. Shire Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 66. Greencross Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Neurodegenerative Disease Market Insights Forecast to 2030
Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030
Global Metabolic Disorder Therapeutics Market Insights Forecast to 2030
Mitochondrial Disorders Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Autism Spectrum Disorder Diagnostics Market Insights Forecast to 2030
Global Central Nervous System Biomarkers Market Insights Forecast to 2030
Global Learning Disability Treatment Market Insights Forecast to 2030
Global Diabetic Neurological Disorder Therapeutic Drug Market Insights Forecast to 2030
Global Genetic Obesity Drug Market Research Report 2025
Global Neurodegenerative Disease Treatment Market Research Report 2024
Global Gaucher Disease GD Drugs Market Insights Forecast to 2030
Global Neurorehabilitation Therapy Market Insights Forecast to 2030
Global Sleep Movement Disorder Drug Market Insights Forecast to 2030
Global Addictions Therapeutics Market Insights Forecast to 2030
Global Alzheimers and Parkinsons Diseases Market Insights Forecast to 2030
Global Neurodegenerative Disorder Therapeutics Market Research Report 2024
Global Brain Monitoring Market Insights Forecast to 2030
Amino Acid Metabolism Disorder Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hereditary Testing Market Insights Forecast to 2030
Rare Neurodegenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions